NewAmsterdam Pharma Company N.V.
Status: Publicly traded
Direct answer
NewAmsterdam Pharma Company N.V. is publicly traded on NASDAQ under the ticker NAMS.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also...
Can you invest in NewAmsterdam Pharma Company N.V.?
Yes. NewAmsterdam Pharma Company N.V. is publicly traded on NASDAQ under the ticker NAMS.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for NewAmsterdam Pharma Company N.V.
Detailed equity research is provided by MarketSnap.